Pretomanid
- Generic Name
- Pretomanid
- Brand Names
- 普瑞尼, Dovprela (previously Pretomanid FGK)
- Drug Type
- Small Molecule
- Chemical Formula
- C14H12F3N3O5
- CAS Number
- 187235-37-6
- Unique Ingredient Identifier
- 2XOI31YC4N
- Background
Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy regimens. Pretomanid is an antimycobacteri...
- Indication
Pretomanid is indicated, as part of a combination regimen with bedaquiline and linezolid, for the treatment of adults with pulmonary tuberculosis (TB) that is resistant to isoniazid, rifamycins, a fluoroquinolone and a second-line injectable antibacterial drug or adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or no...
- Associated Conditions
- Pulmonary Rifampicin- and Isoniazid-Resistant Tuberculosis, Pulmonary Tuberculosis resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug
- Associated Therapies
- -
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 690
- Registration Number
- NCT06441006
- Locations
- 🇲🇩
Institute of Phthisiopneumology Chiril Dragniuc, Chisinau, Moldova, Republic of
🇲🇳National Center for Communicable Diseases, Ulaanbaatar, Mongolia
🇵🇪Hospital Nacional Hipólito Unanue, Lima, Peru
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-13
- Target Recruit Count
- 315
- Registration Number
- NCT06192160
- Locations
- 🇺🇬
12401, Joint Clinical Research Centre (JCRC)/Kampala CRS, Kampala, Uganda
🇲🇼30301, Blantyre CRS, Blantyre, Malawi
🇲🇼12001, Malawi CRS, Lilongwe, Malawi
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 300
- Registration Number
- NCT06058299
- Locations
- 🇵🇭
Care Clinical Trial Group Inc., Dasmariñas, Philippines
🇬🇪National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
🇵🇭Tropical Disease Foundation, Makati City, Philippines
A Pan-TB Regimen Targeting Host and Microbe
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- The Aurum Institute NPC
- Target Recruit Count
- 352
- Registration Number
- NCT05686356
- Locations
- 🇲🇿
Instituto Nacional de Saúde, Maputo, Mozambique
🇿🇦Clinical HIV Research Unit, Durban, South Africa
🇿🇦The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa
Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2024-02-07
- Target Recruit Count
- 72
- Registration Number
- NCT05586230
- Locations
- 🇮🇳
Site 31441, BJMC CRS, Pune, India
🇿🇦Site 31976, PHRU Matlosana CRS, Klerksdorp, North West Province, South Africa
🇧🇷Site 5071, Instituto de Puericultura e Pediatria Martagao Gesteira CRS, Rio De Janeiro, Brazil
Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India
- Conditions
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Tuberculosis Research Centre, India
- Target Recruit Count
- 400
- Registration Number
- NCT05040126
- Locations
- 🇮🇳
S N Medical College, Agra, Uttarpradesh, India
Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 48
- Registration Number
- NCT04309656
- Locations
- 🇺🇸
Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States
Economic Evaluation of New MDR TB Regimens
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Medecins Sans Frontieres, Netherlands
- Target Recruit Count
- 73
- Registration Number
- NCT04207112
- Locations
- 🇿🇦
THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa
🇿🇦King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa
🇧🇾Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 26
- Registration Number
- NCT04179500
- Locations
- 🇿🇦
CHRU, Sizwe Tropical Diseases Hospital, Johannesburg, South Africa
🇿🇦Isango Lethemba TB Research Unit Empilweni TB Hospital, Port Elizabeth, South Africa
🇿🇦The Aurum Institute: Rustenburg Clinical Research Centre, Rustenburg, South Africa
PRACTECAL-PKPD Sub Study
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Medecins Sans Frontieres, Netherlands
- Target Recruit Count
- 240
- Registration Number
- NCT04081077
- Locations
- 🇧🇾
Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus
🇿🇦King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa
🇿🇦THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.